Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merus Labs, a specialty pharmaceutical company engaged in acquisition and licensing of pharmaceutical products, has said that its wholly owned subsidiary and Methapharm have executed a binding letter of intent (LOI), for the licensing, registration, and distribution of specific pharmaceutical products and medical devices in Canada.
Subscribe to our email newsletter
Merus said that the portfolio of products include anti-fungal creams and also certain wound care products such as Hydrogel, ulcer wound, and composite multi-layered dressings
Ahmad Doroudian, president and CEO of Merus, said: “Methapharm is expected to provide Merus with the infrastructure, and regulatory expertise in order to propel the company into the future. We look forward to the expansion of our partnership with Methapharm in the near future.”
Methapharm is a cGMP specialty pharmaceutical company into the commercialisation and marketing of niche pharmaceutical products and devices in specific therapeutic categories. The company markets its own proprietary products as well as products from partner companies.